

Clinical Policy: Sacituzumab Govitecan-hziy (Trodelvy)

Reference Number: PA.CP.PHAR.475

Effective Date: 07/2020

Last Review Date: 04/2026

Description

Sacituzumab govitecan-hziy (Trodelvy[®]) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate.

FDA Approved Indication(s)

Trodelvy is indicated for the treatment of adult patients with

- Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
- Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness[®] that Trodelvy is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Breast Cancer (must meet all):

1. Diagnosis of unresectable, metastatic or no response to preoperative systemic therapy breast cancer;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Documentation of one of the following (a or b):
 - a. Triple negative (i.e., estrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2 [HER2]-negative) disease;
 - b. Hormone receptor (HR)-positive, HER2-negative disease;
5. For TNBC, prescribed in one of the following ways (a or b):
 - a. In combination with pembrolizumab, and (i):
 - i. Tumor expresses PD-L1 (Combined Positive Score [CPS] $\geq$ 10);
 - b. As a single agent, and one of the following (i or ii):
 - i. Failure of one or more prior regimens (*see Appendix B*);
 - ii. Tumor expresses PD-L1 CPS $<$ 10 and disease is negative for germline BRCA 1/2 pathogenic variant;
6. For HR-positive, HER2-negative disease, all of the following (a-d):
 - a. Failure of an endocrine based therapy (*see Appendix B*);

- b. Failure of two or more additional prior regimens (*see Appendix B*);
- c. At least one of the prior regimens administered for metastatic disease;
- d. Prescribed as a single agent;
- 7. Request meets one of the following (a or b):
 - a. Dose does not exceed 10 mg/kg on days 1 and 8 of each 21-day cycle;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 12 months

B. Bladder Cancer (must meet all):

- 1. For locally advanced or metastatic urothelial cancer: provider attestation of acknowledgement of the FDA's withdrawal of this indication due to failure to improve overall survival (OS) and associated higher number of deaths from adverse events with Trodelvy compared to alternative treatments (*see Appendix D*);
- 2. One of the following (a or b):
 - a. Diagnosis of carcinoma of the urethra, primary carcinoma of urethra, upper GU tract tumors, urothelial carcinoma of the prostate, bladder cancer;
 - b. Any other category 1, 2A, or 2B NCCN-recommended uses not listed;
- 3. Prescribed by or in consultation with an oncologist;
- 4. Age ≥ 18 years;
- 5. Prescribed as second-line or subsequent-line systemic therapy;
- 6. Prescribed as a single agent;
- 7. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 12 months

C. Other diagnoses/indications

- 1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

II. Continued Therapy

A. All Indications in Section I (must meet all):

- 1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies;
- 2. Member is responding positively to therapy;
- 3. For locally advanced or metastatic urothelial cancer, provider attestation of acknowledgement of the FDA's withdrawal of this indication due to failure to improve OS and associated higher number of deaths from adverse events with Trodelvy compared to alternative treatments (*see Appendix D*);
- 4. If request is for a dose increase, request meets one of the following (a or b):
 - a. New dose does not exceed 10 mg/kg on days 1 and 8 of each 21-day cycle;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

HER2: human epidermal growth factor receptor 2

HR: hormone receptor

mTNBC: metastatic triple-negative breast cancer

mUC: metastatic urothelial cancer

PD-1: programmed death receptor-1

PD-L1: programmed death-ligand

OS: overall survival

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
Examples of systemic therapies for recurrent unresectable or metastatic breast cancer		
paclitaxel	Varies	Varies
Abraxane [®] (albumin-bound paclitaxel)	Varies	Varies
docetaxel (Taxotere [®])	Varies	Varies
doxorubicin	Varies	Varies
Liposomal doxorubicin (Doxil [®])	50 mg/m ² IV day 1, cycled every 28 days	Varies
capecitabine (Xeloda [®])	1,000-1,250 mg/m ² PO BID on days 1-14, cycled every 21 days	Varies
gemcitabine (Gemzar [®])	800-1,200 mg/m ² IV on days 1,8 and 15, cycled every 28 days	Varies
vinorelbine	Varies	Varies
Halaven [®] (eribulin)	1.4 mg/m ² IV on days 1 and 8, cycled every 21 days	Varies
carboplatin	AUC 6 IV on day 1, cycled every 21-28 days	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
cisplatin	75 mg/m ² IV on day 1, cycled every 21 days	Varies
cyclophosphamide	50 mg PO QD on days 1-21, cycled every 28 days	Varies
epirubicin (Ellence [®])	60-90 mg/m ² IV on day 1, cycled every 21 days	Varies
Ixempra [®] (ixabepilone)	40 mg/m ² IV on day 1, cycled every 21 days	40 mg/m ²
Examples of platinum-containing regimens for urothelial cancer		
DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)	Varies	Varies
gemcitabine with either cisplatin or carboplatin	Varies	Varies
Examples of PD-1 and PD-L1 inhibitors for urothelial cancer		
Keytruda [®] (pembrolizumab)	Varies	Varies
Tecentriq [®] (atezolizumab)	Varies	Varies
Opdivo [®] (nivolumab)	Varies	Varies
Bavencio [®] (avelumab)	800 mg IV infusion once every 2 weeks	Varies
Examples of endocrine based therapy for breast cancer		
Tamoxifen; aromatase inhibitors: anastrozole (Arimidex [®]), letrozole (Femara [®]), exemestane (Aromasin [®])	Varies	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): severe hypersensitivity reaction to Trodelvy
- Boxed warning(s): neutropenia and diarrhea

Appendix D: Withdrawal of Metastatic Urothelial Cancer Indication

- On October 18, 2024, Gilead Sciences, Inc. announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either PD-1 or PD-L1 inhibitor.
- On November 22, 2024, FDA approved revisions to the full prescribing information to voluntarily withdraw the indication for advanced or metastatic urothelial cancer. This decision does not affect the other approved Trodelvy indications.
- This withdrawal was based to the confirmatory phase 3 TROPiCs-04 study, which failed to meet its primary endpoint of OS. The study also showed that Trodelvy was associated with a higher number of deaths from adverse events than the group that received treatment of the physician's choice.

- Patients receiving Trodelvy for metastatic urothelial cancer should discuss their care with their healthcare provider.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
breast cancer	10 mg/kg on days 1 and 8 of each 21-day cycle	10 mg/kg

VI. Product Availability

Single-dose vial: 180 mg lyophilized powder for reconstitution

VII. References

1. Trodelvy Prescribing Information. Morris Plains, NJ: Immunomedics, Inc.; March 2025. Available at: <https://www.trodelvyhcp.com/>. Accessed January 23, 2026.
2. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 2019 Feb 21;380(8):741-51.
3. Sacituzumab govitecan. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed January 30, 2026.
4. National Comprehensive Cancer Network Guidelines. Breast Cancer Version 1.2025. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 30, 2026.
5. National Comprehensive Cancer Network Guidelines. Bladder Cancer Version 3.2025. Available at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed January 30, 2026.
6. Gilead provides update on Phase 3 TROPiCs-01 study. May 30, 2024. Available at: <https://www.gilead.com/news/news-details/2024/gilead-provides-update-on-phase-3-tropics-04-study>. Accessed January 30, 2026.
7. Gilead provides update on U.S. indication for Trodelvy in metastatic urothelial cancer. October 18, 2024. Available at: [https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer#:~:text=Foster%20City%2C%20Calif.%2C%20October,and%20Drug%20Administration%20\(FDA\)](https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer#:~:text=Foster%20City%2C%20Calif.%2C%20October,and%20Drug%20Administration%20(FDA)). Accessed January 23, 2026.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg

Reviews, Revisions, and Approvals	Date
New Policy Created	07/2020

Reviews, Revisions, and Approvals	Date
2Q 2021 annual review: added criteria for new mUC indication; updated breast cancer criteria to add unresectable locally advanced option and clarified that of the two or more prior regimens, at least one of them be for metastatic disease, based on updated FDA-labeling; updated JCode; references reviewed and updated.	04/2021
2Q 2022 annual review: for TNBC: removed “locally advanced” requirement as disease can be local or regional per NCCN; added recurrent urothelial carcinoma indication per NCCN; added criterion for use as single-agent therapy for both TNBC and urothelial cancer per NCCN; references reviewed and updated.	04/2022
2Q 2023 annual review: no significant changes; references reviewed and updated. RT4: added new indication for treatment of HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting	04/2023
2Q 2024 annual review: for TNBC, revised failure of prior regimens from “two or more” to “one or more” per NCCN; references reviewed and updated.	04/2024
2Q 2025 annual review: updated to include withdrawal of previously FDA-approved indication for urothelial cancer and changed to off-label as the use remains NCCN supported; added provider attestation criterion acknowledging FDA withdrawal; added withdrawal information in Appendix D; references reviewed and updated.	04/2025
2Q 2026 annual review: for TNBC, added option to be prescribed as first-line therapy per NCCN; for all indications, extended initial approval duration from 6 to 12 months; references reviewed and updated.	04/2026